Jefferies sets $105 target on Insmed stock with Buy rating

On Tuesday, Jefferies began coverage of Insmed Incorporated (NASDAQ:INSM) with a Buy rating and set a price target of $105.00, adding to the strong bullish consensus among analysts. The stock has delivered an impressive 162% return over the past year, with analyst targets ranging from $89 to $109. According to InvestingPro, six analysts have recently revised their earnings expectations upward for the upcoming period. The research firm cited several factors for the positive outlook, including what they identify as the potential for Insmed’s brensocatib to become a major blockbuster drug for treating bronchiectasis due to its first-in-disease status and strong clinical profile. The company, now valued at $12.3 billion, has demonstrated strong revenue growth of 20.8% in the last twelve months, supporting its expansion trajectory.

Analysts at Jefferies highlighted the high level of enthusiasm among Key Opinion Leaders (KOLs) for brensocatib, suggesting it could lead to a rapid market launch. Additionally, they noted that success in Phase 2 trials for conditions such as CRSsNP and HS could significantly increase the value of brensocatib.

The coverage also mentioned TPIP, Insmed’s inhaler product, which Jefferies believes is well-positioned to compete with mainstream drugs due to its easier dosing. The firm is keeping a close eye on the Phase 2 trial for Pulmonary Arterial Hypertension (PAH) slated for June 2025, viewing it as a crucial event for the company.

Furthermore, Jefferies anticipates the expansion of Insmed’s commercial asset ARIKAYCE to first-line treatment for MAC lung disease, with Phase 3 data expected in the first half of 2026. This potential development was factored into their positive assessment and the establishment of the $105 price target for Insmed’s stock. With a robust current ratio of 5.86, the company maintains strong liquidity to support its development pipeline. For deeper insights into Insmed’s financial health and growth prospects, including exclusive ProTips and comprehensive valuation metrics, explore InvestingPro’s detailed research report.

In other recent news, Insmed Inc. reported mixed financial results for the first quarter of 2025. The company posted an earnings per share (EPS) of -$1.42, slightly missing analysts’ expectations of -$1.35. However, Insmed’s revenue exceeded forecasts, reaching $92.82 million compared to the anticipated $90.78 million. The company highlighted strong international market growth, particularly in Japan and Europe, which saw approximately 50% sales increases. Despite the revenue beat, investor concerns over the EPS miss and anticipated higher spending plans were noted. Insmed is preparing for the launch of brensocatib, with a decision from the FDA expected by August 12. The company maintains a robust cash position of $1.2 billion, supporting its upcoming product launches. Analyst feedback and further company developments were not specifically mentioned in the recent updates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.